We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Safety of Plasma Products Increased by Duplex Virus Assay

By LabMedica International staff writers
Posted on 07 Oct 2010
A single in vitro diagnostic (IVD) assay offers complete coverage of all human genotypes of Human parvovirus B19 (B19V) and Hepatitis A virus (HAV). More...
It will increase the safety of plasma and plasma products.

The in vitro nucleic acid amplification technology (NAT) test simultaneously quantifies B19V genotypes 1, 2, and 3 DNA and detects HAV genotypes I, II, and III RNA in individual samples or pooled plasma samples of human origin. It uses multidye, real-time polymerase chain reaction (RT-PCR) technology, which allows for the simultaneous detection and identification of individual viral targets without the use of complementary discriminatory tests.

Roche Molecular Diagnostics (Pleasanton, CA, USA) announced that the new assay, called the cobas TaqScreen DPX test, is available for use on the cobas s 201 system and is CE marked. The test will allow an increase plasma processing efficiency and may reduce the number of units that are discarded. The highly precise, quantitative values obtained for B19V DNA and the test's high sensitivity for HAV RNA meet current regulatory requirements for plasma intended for further manufacture.

Human plasma is fractionated into components, such as immunoglobulins, albumin, and clotting factors, which have many therapeutic uses. These include treatment of chronic and hereditary diseases and disorders such as hemophilia and primary immunodeficiency diseases. Plasma is also used to treat patients who have suffered severe burns or trauma, and during major surgery.

There have been reports of transmission of B19V through use of plasma and plasma products, particularly coagulation factors. Transmission of HAV has been reported through blood and plasma products. Traditional methods do not easily inactivate these viruses and therefore NAT detection is an important step in ensuring their safety.

"Roche is committed to providing the broadest coverage and most efficient screening tests to ensure the highest safety of blood and plasma products," said Paul Brown, Ph.D., president and CEO of Roche Molecular Diagnostics. "This new test is one more step toward that goal and complements our current cobas TaqScreen tests for the detection of HIV [human immunodeficiency virus], HCV, [Hepatitis C virus] HBV [Hepatitis B virus], and WNV [West Nile virus]."

Related Links:

Roche Molecular Diagnostics



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
New
Silver Member
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.